Establishing Patient-Derived Cancer Cell Cultures and Xenografts in Biliary Tract Cancer

Kang, JiHoon; Lee, Ji-Young; Lee, Sunmin; Kim, Danbee; Lim, Jinyeong; Jun, Ha Ra; Jeon, Soo-Young; Kim, Young-Ae; Park, Hye Seon; Kim, Kyu-Pyo; Chun, Sung; Lee, Hee Jin; Yoo, Changhoon

doi:10.4143/crt.2021.1166

Cited by 2 publications

(16 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PDX-BF has been established from several organs, including the ovary (20,27), uterus (26), pancreas (22,28), kidney (29), lung (24), biliary tract (23), and stomach (13). The engraftment rate is important for preparing xenografts from peritoneal or pleural effusion samples.…”

Section: Discussionmentioning

confidence: 99%

“…The engraftment rate is important for preparing xenografts from peritoneal or pleural effusion samples. PDX-BF was established for 29 and 33 cases of OC (20,27), 1 case of endometrial cancer (26), 3 and 12 cases of pancreatic cancer (22,28), 1 case of renal cancer (29), 2 cases of lung cancer (24), 3 cases of BTC (23), and 4 cases of gastric cancer (13). The success rates were 29% and 31% for OC (20,27), 70% for pancreatic cancer (22), 60% for BTC (23), and 24% for gastric cancer (13).…”

Section: Discussionmentioning

confidence: 99%

“…PDX-BF was established for 29 and 33 cases of OC (20,27), 1 case of endometrial cancer (26), 3 and 12 cases of pancreatic cancer (22,28), 1 case of renal cancer (29), 2 cases of lung cancer (24), 3 cases of BTC (23), and 4 cases of gastric cancer (13). The success rates were 29% and 31% for OC (20,27), 70% for pancreatic cancer (22), 60% for BTC (23), and 24% for gastric cancer (13). The latency periods for tumor growth were 2-12 months and 2-3 months in OC (20,27), 2 months in endometrial cancer (26), and 2-12 weeks in pancreatic cancer (22).…”

Section: Discussionmentioning

confidence: 99%

“…The latency periods for tumor growth were 2-12 months and 2-3 months in OC (20,27), 2 months in endometrial cancer (26), and 2-12 weeks in pancreatic cancer (22). For the factors contributing to the growth rate, these studies revealed successful engraftment for chemotherapy-resistant and poor prognosis cases (13,23,26,28,29). Few reports have compared PDX and PDX-BF in the same cases.…”

Section: Discussionmentioning

confidence: 99%

“…PDX prepared from tumors are reported to be pathologically and genetically similar to primary tumors in the colon (15), stomach (13), lung (16), head and neck (17), uterus (11,12,18,19), and ovary (20,21). Studies related to PDX from body uid (PDX-BF), including peritoneal and pleural effusion samples from pancreatic cancer (22), renal medullary cancer, biliary tract cancer (BTC) (23), lung cancer (24), which is di cult to detect at the early stage and is lethal, and OC, have been published. According to these studies, PDX prepared from peritoneal and pleural effusion samples can retain the histological characteristics of the tumor.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Creation and validation of a patient-derived cancer model using peritoneal and pleural effusion samples from patients with ovarian cancer

Nishie

Tanaka

Murakami

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: The application of personalized cancer treatment based on genetic information and surgical samples has begun in the field of cancer medicine. However, biopsy may be painful for patients with advanced disease that do not qualify for surgical resection. Patient-derived xenografts (PDXs) are cancer models in which patient samples are transplanted into immunodeficient mice. PDXs are expected to be useful for personalized medicine. The aim of this study was to establish a PDX from body fluid (PDX-BF), such as peritoneal and pleural effusion samples,to provide personalized medicine without surgery. Methods PDXs-BF were created from patients with ovarian cancer who had positive cytology findings based on peritoneal and pleural effusion samples. PDXs were also prepared from each primary tumor. The pathological findings based on immunohistochemistry were compared between the primary tumor, PDX, and PDX-BF. Further, genomic profiles and gene expression were evaluated using DNA and RNA sequencing to compare primary tumors, PDXs, and PDX-BF. Results Among the 15 patients, PDX-BF was established for 8 patients (5 high-grade serous carcinoma, 1 carcinosarcoma, 1 low-grade serous carcinoma, and 1 clear cell carcinoma); the successrate was 53%. Histologically, PDXs-BF have features similar to those of primary tumors and PDXs. In particular, PDXs-BF had similar gene mutations and expression patterns to primary tumors and PDXs. Conclusions PDX-BF reproduced primary tumors in terms of pathological features and genomic profiles, including gene mutation and expression. Thus, PDX-BF may be a potential alternative to surgical resection for patients with advanced disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Creation and validation of a patient-derived cancer model using peritoneal and pleural effusion samples from patients with ovarian cancer

Nishie

Tanaka

Murakami

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

Creation and Validation of Patient-Derived Cancer Model Using Peritoneal and Pleural Effusion in Patients with Advanced Ovarian Cancer: An Early Experience

Nishie,

Tanaka,

Hirosuna

et al. 2024

JCM

View full text Add to dashboard Cite

Background: The application of personalized cancer treatment based on genetic information and surgical samples has begun in the field of cancer medicine. However, a biopsy may be painful for patients with advanced diseases that do not qualify for surgical resection. Patient-derived xenografts (PDXs) are cancer models in which patient samples are transplanted into immunodeficient mice. PDXs are expected to be useful for personalized medicine. The aim of this study was to establish a PDX from body fluid (PDX-BF), such as peritoneal and pleural effusion samples, to provide personalized medicine without surgery. Methods: PDXs-BF were created from patients with ovarian cancer who had positive cytology findings based on peritoneal and pleural effusion samples. PDXs were also prepared from each primary tumor. The pathological findings based on immunohistochemistry were compared between the primary tumor, PDX, and PDX-BF. Further, genomic profiles and gene expression were evaluated using DNA and RNA sequencing to compare primary tumors, PDXs, and PDX-BF. Results: Among the 15 patients, PDX-BF was established for 8 patients (5 high-grade serous carcinoma, 1 carcinosarcoma, 1 low-grade serous carcinoma, and 1 clear cell carcinoma); the success rate was 53%. Histologically, PDXs-BF have features similar to those of primary tumors and PDXs. In particular, PDXs-BF had similar gene mutations and expression patterns to primary tumors and PDXs. Conclusions: PDX-BF reproduced primary tumors in terms of pathological features and genomic profiles, including gene mutation and expression. Thus, PDX-BF may be a potential alternative to surgical resection for patients with advanced disease.

show abstract

Establishing Patient-Derived Cancer Cell Cultures and Xenografts in Biliary Tract Cancer

Cited by 2 publications

References 30 publications

Creation and validation of a patient-derived cancer model using peritoneal and pleural effusion samples from patients with ovarian cancer

Creation and validation of a patient-derived cancer model using peritoneal and pleural effusion samples from patients with ovarian cancer

Creation and Validation of Patient-Derived Cancer Model Using Peritoneal and Pleural Effusion in Patients with Advanced Ovarian Cancer: An Early Experience

Contact Info

Product

Resources

About